Tau protein abnormalities are key pathogenic features of Alzheimer disease and other neurodegenerative diseases. In 2015, new studies of the less common tauopathies, including progressive

supranuclear palsy, chronic traumatic encephalopathy and frontotemporal lobar degeneration, have identified _in vivo_ biomarkers and mechanisms that initiate tau pathology. Access through

your institution Buy or subscribe This is a preview of subscription content, access via your institution RELEVANT ARTICLES Open Access articles citing this article. * APPLYING ANTIBODIES

INSIDE CELLS: PRINCIPLES AND RECENT ADVANCES IN NEUROBIOLOGY, VIROLOGY AND ONCOLOGY * Congcong Zhang * , Rina M. Ötjengerdes *  … Andrea L. J. Marschall _BioDrugs_ Open Access 16 April 2020

about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Wang, Y. & Mandelkow, E. Tau in physiology and pathology. _Nat. Rev. Neurosci._ 17, 22–35

(2015). Article  CAS  Google Scholar  * Goedert, M. Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled Aβ, tau, and α-synuclein. _Science_ 349,

1255555 (2015). Article  Google Scholar  * Nag, S. _ et al_. Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. _Ann. Neurol._ 77, 942–952 (2015). Article  CAS 

Google Scholar  * Schneider, J. A., Arvanitakis, Z., Leurgans, S. E. & Bennett, D. A. The neuropathology of probable Alzheimer disease and mild cognitive impairment. _Ann. Neurol._ 66,

200–208 (2009). Article  Google Scholar  * Zhao, Y. _ et al_. Appoptosin-mediated caspase cleavage of tau contributes to progressive supranuclear palsy pathogenesis. _Neuron_ 87, 963–975

(2015). Article  CAS  Google Scholar  * Hoglinger, G. U. _ et al_. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. _Nat. Genet._ 43,

699–705 (2011). Article  Google Scholar  * Kondo, A. _ et al_. Antibody against early driver of neurodegeneration _cis_ P-tau blocks brain injury and tauopathy. _Nature_ 523, 431–436 (2015).

Article  Google Scholar  * Olivera, A. _ et al_. Peripheral total tau in military personnel who sustain traumatic brain injuries during deployment. _JAMA Neurol._ 72, 1109–1116 (2015).

Article  Google Scholar  * Rohrer, J. D. _ et al_. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative

(GENFI) study: a cross-sectional analysis. _Lancet Neurol._ 14, 253–262 (2015). Article  Google Scholar  * Johnson, K. A. _ et al_. Tau positron emission tomographic imaging in aging and

early Alzheimer disease. _Ann. Neurol._ http://dx.doi.org/10.1002/ana.24546 (2015). Download references ACKNOWLEDGEMENTS J.C.R. and A.L.B. are supported by NIH (grants U54NS092089 and

R01AG038791) and the Tau Consortium. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Neurology, Clinical Trials Program, Memory and Aging Center, University of California, San

Francisco, 675 Nelson Rising Lane, Suite 190, MC 1207, San Francisco, 94143, California, USA Julio C. Rojas & Adam L. Boxer Authors * Julio C. Rojas View author publications You can also

search for this author inPubMed Google Scholar * Adam L. Boxer View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to

Adam L. Boxer. ETHICS DECLARATIONS COMPETING INTERESTS A.L.B. has received research support from Avid, Biogen, Bristol Myers Squibb, C2N Diagnostics, Cortice Biosciences, Eli Lilly, Forum

Pharmaceuticals, Genentech and TauRx. He has served as a consultant for Asceneuron, Ipierian, Ionis (formerly Isis) Pharmaceuticals, Janssen and Merck. He serves on a Data and Safety

Monitoring Board for Neurogenetics Pharmaceuticals. He has stock and/or options in Alector and Delos. J.C.R. declares no competing interests. RELATED LINKS WEB LINKS The Genetic FTD

Initiative (GENFI) Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) POWERPOINT SLIDES POWERPOINT SLIDE FOR FIG. 1 RIGHTS AND PERMISSIONS Reprints and

permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Rojas, J., Boxer, A. Targeting tauopathies for therapeutic translation. _Nat Rev Neurol_ 12, 74–76 (2016).

https://doi.org/10.1038/nrneurol.2016.5 Download citation * Published: 22 January 2016 * Issue Date: February 2016 * DOI: https://doi.org/10.1038/nrneurol.2016.5 SHARE THIS ARTICLE Anyone

you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the

Springer Nature SharedIt content-sharing initiative